Acerta Pharma & AstraZeneca v. Alembic: BTK Inhibitor CLL Patent Ends in Consent Judgment
Acerta Pharma, AstraZeneca, and Merck Sharp & Dohme brought an infringement action in Delaware against Alembic over US10272083B2, a patent protecting methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor. The case closed after 383 days via a consent judgment dismissing all claims with prejudice and no costs awarded to either side.
AstraZeneca’s BTK Inhibitor Patent Resolved by Consent in Delaware
Filed on 19 May 2023 in the District of Delaware before Judge Gregory B. Williams, this infringement action was brought by Acerta Pharma B.V., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, and Merck Sharp & Dohme B.V. against Alembic and Alembic Pharmaceuticals, Inc. The asserted patent — US10272083B2 — covers methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) using a BTK inhibitor, consistent with AstraZeneca’s acalabrutinib franchise (marketed as Calquence).
The case closed on 5 June 2024 via a consent judgment, dismissing all claims, affirmative defenses, and demands between AstraZeneca, MSD, and Alembic with prejudice. Critically, the order expressly excludes costs, disbursements, and attorneys’ fees for any party. A dismissal with prejudice bars Alembic from relitigating the same claims in the same forum, while the no-costs provision suggests the resolution was negotiated rather than contested to judgment.
At 383 days, the case resolved faster than many fully litigated ANDA patent disputes in Delaware, suggesting the parties reached a negotiated arrangement — potentially including a licensing or entry date agreement — before substantive motion practice concluded. The public record does not disclose specific commercial terms, and the precise scope of any agreed market access for Alembic’s generic product remains unknown from the consent judgment alone.
Filing to Consent Judgment in 383 days
383 days from filing to consent judgment — typical for ANDA-related pharma patent settlements in Delaware
Consent judgment with prejudice: what the resolution means for both parties
Consent judgment dismisses all claims with prejudice
A consent judgment is a court-ordered disposition agreed to by both parties. Here, all claims, affirmative defenses, and demands were dismissed with prejudice — meaning Alembic cannot re-file the same claims in the same court. Unlike a default or trial judgment, a consent judgment reflects a negotiated resolution, though its specific commercial terms are not made public in the filing.
Negotiated resolutionAstraZeneca secures prejudice bar against Alembic re-litigation
Dismissal with prejudice protects AstraZeneca and Acerta Pharma from Alembic relitigating the same infringement and invalidity positions in this forum. US10272083B2 remains in force. Any market entry by Alembic for a BTK inhibitor product treating CLL/SLL would likely be governed by terms agreed privately — which may include a licensed entry date tied to patent expiry or earlier milestones.
Patent preservedAlembic’s path to market likely shaped by undisclosed consent terms
For Alembic, the consent judgment closes the litigation without a finding of invalidity or non-infringement in its favour. This is typical of ANDA settlements where the generic manufacturer agrees to a delayed or licensed entry date. The absence of a public invalidity ruling means US10272083B2 continues to carry full presumptive validity against other potential challengers.
No invalidity findingBTK inhibitor IP landscape remains intact post-settlement
Because the case ended without substantive adjudication on validity or infringement, the BTK inhibitor patent estate around acalabrutinib faces no precedential weakening from this proceeding. Competitors and other generic filers should note that the patent survives unchallenged on the public record from this docket, and any future ANDA filers would need to mount their own independent validity challenges.
IP landscape unchangedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Acerta Pharma B.V. | Individual | Pharmaceutical group — holder of US10272083B2 covering BTK inhibitor CLL/SLL treatment methodsSearch in Eureka ↗ |
| Co-Plaintiff | AstraZeneca AB | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Merck Sharp & Dohme, B.V. | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Astrazeneca Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Co-Plaintiff | AstraZeneca UK Limited | Individual | Search in Eureka ↗ |
| Defendant | Alembic | Individual | Alembic Pharmaceuticals — generic drug manufacturer seeking market entry for a BTK inhibitor productSearch in Eureka ↗ |
| Co-Defendant | Alembic Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Acerta Pharma B.V.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Acerta Pharma B.V.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Acerta Pharma B.V.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing AlembicSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s language — ‘dismissed with prejudice and without costs, disbursements or attorneys’ fees’ — is carefully drafted to be bilateral and cost-neutral, strongly suggesting a negotiated commercial resolution rather than a capitulation by either side. The explicit limitation ‘and only between AstraZeneca, MSD, and Alembic’ preserves the plaintiffs’ rights against any other parties and signals that the settlement scope was deliberately bounded. No merits determination was made.
US10272083B2 — BTK inhibitor methods for treating CLL and SLL
US10272083B2 — filed under application number US15/112968 — protects methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) using a Bruton’s tyrosine kinase (BTK) inhibitor. BTK inhibitors represent a major advance in haematological oncology, replacing chemotherapy regimens with targeted oral therapies. This patent is consistent with the intellectual property estate supporting acalabrutinib (Calquence), AstraZeneca and Acerta Pharma’s second-generation BTK inhibitor approved for CLL and SLL indications.
For the oncology pharmaceutical sector, method-of-treatment patents over BTK inhibitors carry significant commercial weight — they can gate generic and biosimilar market entry even after compound patents expire. The multi-entity plaintiff structure (Acerta Pharma, four AstraZeneca entities, and MSD) reflects the complexity of co-development and co-commercialisation arrangements common in large oncology partnerships. Any company developing or commercialising a BTK inhibitor for CLL or SLL indications should assess whether their proposed label overlaps with the claim scope of US10272083B2.
Should you run an FTO against US10272083B2?
Any pharmaceutical company — branded or generic — developing a BTK inhibitor product with a CLL or SLL indication should conduct a freedom-to-operate analysis against US10272083B2. This includes ANDA filers, 505(b)(2) applicants, and companies developing next-generation BTK inhibitors with overlapping mechanism of action or clinical indication. The patent’s method-of-treatment claims may extend beyond the specific compound to cover the therapeutic use broadly.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US10272083B2 against your product’s proposed label, identify prior art that may support design-around strategies, and surface related AstraZeneca and Acerta Pharma patent families relevant to the BTK inhibitor space. Eureka also tracks Orange Book listings and ANDA litigation history to give R&D and IP teams a complete picture of freedom-to-operate risk before IND filing or ANDA submission.
Run a freedom-to-operate analysis on US10272083B2 to assess your product’s exposure
Run FTO in Eureka →Similar BTK inhibitor and haematological oncology patent cases in Delaware
Delaware District Court has been a recurring venue for BTK inhibitor and CLL-related ANDA patent disputes. These cases illustrate comparable enforcement and consent resolution patterns.
What this case signals for the BTK inhibitor and oncology patent landscape
A consent judgment with prejudice in under 13 months suggests structured negotiation — with implications for other generics eyeing AstraZeneca’s CLL franchise.
Early consent judgments in ANDA cases often signal licensed entry deals
When ANDA patent disputes close via consent judgment with prejudice and no cost awards within 12–15 months, it typically signals a negotiated entry date or licensing arrangement. Companies monitoring the BTK inhibitor generic market should track Alembic’s ANDA status and any subsequent FDA approval timelines for signals on when competition may materialise.
US10272083B2 remains unweakened — full presumptive validity preserved
No invalidity findings or claim constructions entered the public record from this case. For AstraZeneca, this preserves the patent’s strength for enforcement against subsequent ANDA filers. For generic manufacturers, it means any challenge to US10272083B2 must begin without the benefit of prior art arguments already tested in adversarial proceedings from this docket.
B.V. v Alembic — key questions answered
US10272083B2 was the sole patent asserted. It covers methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) using a BTK inhibitor. The patent was filed under application number US15/112968 and is associated with AstraZeneca and Acerta Pharma’s acalabrutinib (Calquence) franchise.
The case was resolved by a consent judgment entered on 5 June 2024, dismissing all claims, affirmative defenses, and demands with prejudice and without costs. A consent judgment reflects a negotiated agreement between the parties. The with-prejudice designation bars Alembic from relitigating the same claims, but no public merits determination — on validity or infringement — was made.
The multi-plaintiff structure — including Acerta Pharma, four AstraZeneca entities, and Merck Sharp & Dohme B.V. — is consistent with co-development and co-commercialisation arrangements common in oncology. MSD has been a commercial partner for acalabrutinib in certain markets. All rights-holders with standing typically join as co-plaintiffs in ANDA patent infringement actions to ensure standing and enforce all relevant commercial interests.
No. The consent judgment explicitly states it applies ‘only between AstraZeneca, MSD, and Alembic.’ It has no preclusive or precedential effect on other ANDA filers or challengers. US10272083B2 remains in force with full presumptive validity, and any other generic manufacturer would need to mount an independent challenge to the patent’s validity or assert non-infringement separately.
The express exclusion of costs, disbursements, and attorneys’ fees in the consent judgment strongly suggests a bilaterally negotiated resolution rather than a one-sided outcome. In ANDA litigation, cost-neutral dismissals with prejudice are commonly associated with settlement agreements that include commercially sensitive terms — such as a licensed generic entry date — which are not disclosed in the public court record.
PatSnap Eureka searches patents and litigation data to answer instantly.